1. Home
  2. AZTR vs ARTL Comparison

AZTR vs ARTL Comparison

Compare AZTR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.28

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.29

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZTR
ARTL
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
AZTR
ARTL
Price
$0.28
$1.29
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$4.00
$30.00
AVG Volume (30 Days)
315.9K
130.0K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$1.15
52 Week High
$4.33
$28.60

Technical Indicators

Market Signals
Indicator
AZTR
ARTL
Relative Strength Index (RSI) 36.30 31.24
Support Level $0.27 $1.48
Resistance Level $0.33 $1.64
Average True Range (ATR) 0.03 0.16
MACD 0.00 -0.02
Stochastic Oscillator 14.52 15.05

Price Performance

Historical Comparison
AZTR
ARTL

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: